How much profit has Astellas Pharma made this year?
Astellas Pharma has made 17.05 B JPY this year.
In 2024, Astellas Pharma's profit amounted to 17.05 B JPY, a -82.73% increase from the 98.71 B JPY profit recorded in the previous year.
YEAR | NET INCOME (undefined JPY) |
---|---|
2027e | 215.95 |
2026e | 149.8 |
2025e | 56.96 |
2024 | 17.05 |
2023 | 98.71 |
2022 | 124.09 |
2021 | 120.59 |
2020 | 195.41 |
2019 | 222.27 |
2018 | 164.68 |
2017 | 218.7 |
2016 | 193.69 |
2015 | 135.86 |
2014 | 90.87 |
2013 | 82.85 |
2012 | 78.23 |
2011 | 67.65 |
2010 | 122.26 |
2009 | 170.99 |
2008 | 177.44 |
2007 | 131.29 |
2006 | 103.57 |
2005 | 33.67 |
3 years
5 years
10 years
25 Years
Max
Gain insights into Astellas Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Astellas Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Astellas Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Astellas Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Astellas Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Astellas Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Astellas Pharma’s growth potential.
Date | Astellas Pharma Revenue | Astellas Pharma EBIT | Astellas Pharma Net Income |
---|---|---|---|
2027e | 1.96 T undefined | 477.92 B undefined | 215.95 B undefined |
2026e | 1.83 T undefined | 441.88 B undefined | 149.8 B undefined |
2025e | 1.76 T undefined | 328.76 B undefined | 56.96 B undefined |
2024 | 1.6 T undefined | 124.61 B undefined | 17.05 B undefined |
2023 | 1.52 T undefined | 231.65 B undefined | 98.71 B undefined |
2022 | 1.3 T undefined | 218.15 B undefined | 124.09 B undefined |
2021 | 1.25 T undefined | 250.93 B undefined | 120.59 B undefined |
2020 | 1.3 T undefined | 267.48 B undefined | 195.41 B undefined |
2019 | 1.31 T undefined | 288.23 B undefined | 222.27 B undefined |
2018 | 1.3 T undefined | 277.69 B undefined | 164.68 B undefined |
2017 | 1.31 T undefined | 273.81 B undefined | 218.7 B undefined |
2016 | 1.37 T undefined | 267.18 B undefined | 193.69 B undefined |
2015 | 1.25 T undefined | 210.64 B undefined | 135.86 B undefined |
2014 | 1.14 T undefined | 187.83 B undefined | 90.87 B undefined |
2013 | 1.01 T undefined | 153.87 B undefined | 82.85 B undefined |
2012 | 969.39 B undefined | 131.52 B undefined | 78.23 B undefined |
2011 | 953.95 B undefined | 119.18 B undefined | 67.65 B undefined |
2010 | 974.88 B undefined | 186.41 B undefined | 122.26 B undefined |
2009 | 965.7 B undefined | 250.4 B undefined | 170.99 B undefined |
2008 | 972.59 B undefined | 275.91 B undefined | 177.44 B undefined |
2007 | 920.62 B undefined | 189.39 B undefined | 131.29 B undefined |
2006 | 879.36 B undefined | 190.4 B undefined | 103.57 B undefined |
2005 | 447.05 B undefined | 96.1 B undefined | 33.67 B undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2005 | 447.05 B JPY | 96.1 B JPY | 33.67 B JPY |
2006 | 879.36 B JPY | 190.4 B JPY | 103.57 B JPY |
2007 | 920.62 B JPY | 189.39 B JPY | 131.29 B JPY |
2008 | 972.59 B JPY | 275.91 B JPY | 177.44 B JPY |
2009 | 965.7 B JPY | 250.4 B JPY | 170.99 B JPY |
2010 | 974.88 B JPY | 186.41 B JPY | 122.26 B JPY |
2011 | 953.95 B JPY | 119.18 B JPY | 67.65 B JPY |
2012 | 969.39 B JPY | 131.52 B JPY | 78.23 B JPY |
2013 | 1.01 T JPY | 153.87 B JPY | 82.85 B JPY |
2014 | 1.14 T JPY | 187.83 B JPY | 90.87 B JPY |
2015 | 1.25 T JPY | 210.64 B JPY | 135.86 B JPY |
2016 | 1.37 T JPY | 267.18 B JPY | 193.69 B JPY |
2017 | 1.31 T JPY | 273.81 B JPY | 218.7 B JPY |
2018 | 1.3 T JPY | 277.69 B JPY | 164.68 B JPY |
2019 | 1.31 T JPY | 288.23 B JPY | 222.27 B JPY |
2020 | 1.3 T JPY | 267.48 B JPY | 195.41 B JPY |
2021 | 1.25 T JPY | 250.93 B JPY | 120.59 B JPY |
2022 | 1.3 T JPY | 218.15 B JPY | 124.09 B JPY |
2023 | 1.52 T JPY | 231.65 B JPY | 98.71 B JPY |
2024 | 1.6 T JPY | 124.61 B JPY | 17.05 B JPY |
2025e | 1.76 T JPY | 328.76 B JPY | 56.96 B JPY |
2026e | 1.83 T JPY | 441.88 B JPY | 149.8 B JPY |
2027e | 1.96 T JPY | 477.92 B JPY | 215.95 B JPY |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Astellas Pharma's sales revenue. A higher gross margin percentage indicates that the Astellas Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Astellas Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Astellas Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Astellas Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Astellas Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Astellas Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Astellas Pharma Gross margin | Astellas Pharma Profit margin | Astellas Pharma EBIT margin | Astellas Pharma Profit margin |
---|---|---|---|
2027e | 81.76 % | 24.34 % | 11 % |
2026e | 81.76 % | 24.09 % | 8.17 % |
2025e | 81.76 % | 18.69 % | 3.24 % |
2024 | 81.76 % | 7.77 % | 1.06 % |
2023 | 81.01 % | 15.25 % | 6.5 % |
2022 | 80.48 % | 16.83 % | 9.57 % |
2021 | 80.31 % | 20.08 % | 9.65 % |
2020 | 78.73 % | 20.56 % | 15.02 % |
2019 | 77.64 % | 22.06 % | 17.01 % |
2018 | 77.37 % | 21.36 % | 12.66 % |
2017 | 75.57 % | 20.88 % | 16.67 % |
2016 | 75.55 % | 19.46 % | 14.11 % |
2015 | 73.29 % | 16.89 % | 10.89 % |
2014 | 71 % | 16.48 % | 7.97 % |
2013 | 67.77 % | 15.3 % | 8.24 % |
2012 | 67.13 % | 13.57 % | 8.07 % |
2011 | 68.97 % | 12.49 % | 7.09 % |
2010 | 70.33 % | 19.12 % | 12.54 % |
2009 | 72.62 % | 25.93 % | 17.71 % |
2008 | 71.28 % | 28.37 % | 18.24 % |
2007 | 69.02 % | 20.57 % | 14.26 % |
2006 | 68.66 % | 21.65 % | 11.78 % |
2005 | 68.13 % | 21.5 % | 7.53 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2005 | 68.13 % | 21.5 % | 7.53 % |
2006 | 68.66 % | 21.65 % | 11.78 % |
2007 | 69.02 % | 20.57 % | 14.26 % |
2008 | 71.28 % | 28.37 % | 18.24 % |
2009 | 72.62 % | 25.93 % | 17.71 % |
2010 | 70.33 % | 19.12 % | 12.54 % |
2011 | 68.97 % | 12.49 % | 7.09 % |
2012 | 67.13 % | 13.57 % | 8.07 % |
2013 | 67.77 % | 15.3 % | 8.24 % |
2014 | 71 % | 16.48 % | 7.97 % |
2015 | 73.29 % | 16.89 % | 10.89 % |
2016 | 75.55 % | 19.46 % | 14.11 % |
2017 | 75.57 % | 20.88 % | 16.67 % |
2018 | 77.37 % | 21.36 % | 12.66 % |
2019 | 77.64 % | 22.06 % | 17.01 % |
2020 | 78.73 % | 20.56 % | 15.02 % |
2021 | 80.31 % | 20.08 % | 9.65 % |
2022 | 80.48 % | 16.83 % | 9.57 % |
2023 | 81.01 % | 15.25 % | 6.5 % |
2024 | 81.76 % | 7.77 % | 1.06 % |
2025e | 81.76 % | 18.69 % | 3.24 % |
2026e | 81.76 % | 24.09 % | 8.17 % |
2027e | 81.76 % | 24.34 % | 11 % |
The profit margins of Astellas Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Astellas Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Evaluating Astellas Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Astellas Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
When Astellas Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Astellas Pharma has made 17.05 B JPY this year.
The profit has increased by -82.73% compared to last year fallen
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
Astellas Pharma publishes its earnings in the form of quarterly or annual reports.
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
The profits of Astellas Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
You can learn more about the earnings of Astellas Pharma by reviewing the quarterly or annual reports or following the company presentations.
Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.18 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.
The current dividend yield of Astellas Pharma is 4.18 %.
Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.
Astellas Pharma paid dividends every year for the past 23 years.
For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.28 %.
Astellas Pharma is assigned to the 'Health' sector.
To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.
The last dividend was paid out on 12/1/2024.
In the year 2023, Astellas Pharma distributed 65 JPY as dividends.
The dividends of Astellas Pharma are distributed in JPY.
The Astellas Pharma stock can be added to a savings plan with the following providers: Consorsbank
Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.